Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6020358 | AMGEN INC | Substituted phenethylsulfones and method of reducing TNFα levels |
Oct, 2018
(5 years ago) | |
US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(4 months ago) | |
US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(1 year, 1 month ago) | |
US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(1 year, 1 month ago) | |
US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(10 years from now) | |
US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
New Indication(I-884) | Dec 20, 2024 |
M(M-299) | Jul 20, 2026 |
New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
New Indication(I-694) | Sep 23, 2017 |
New Indication(I-803) | Jul 19, 2022 |
M(M-257) | Apr 10, 2023 |
NCE-1 date: 21 March, 2018
Market Authorisation Date: 21 March, 2014
Treatment: Use of otezla (apremilast) for the treatment of psoriatic arthritis; Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for...
Dosage: TABLET;ORAL